|
1
|
Borali E and De Giacomo C: Clostridium
difficile infection in children: A review. J Pediatr
Gastroenterol Nutr. 63:e130–e140. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Borali E, Ortisi G, Moretti C, Stacul EF,
Lipreri R, Gesu GP and De Giacomo C: Community-acquired
Clostridium difficile infection in children: A retrospective
study. Dig Liver Dis. 47:842–846. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ananthakrishnan AN: Clostridium
difficile infection: Epidemiology, risk factors and management.
Nat Rev Gastroenterol Hepatol. 8:17–26. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kuntz JL, Johnson ES, Raebel MA, Petrik
AF, Yang X, Thorp ML, Spindel SJ, Neil N and Smith DH: Epidemiology
and healthcare costs of incident Clostridium difficile
infections identified in the outpatient healthcare setting. Infect
Control Hosp Epidemiol. 33:1031–1038. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Rupnik M, Wilcox MH and Gerding DN:
Clostridium difficile infection: New developments in
epidemiology and pathogenesis. Nat Rev Microbiol. 7:526–536.
2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shim JO: Clostridium difficile in
children: To treat or not to treat? Pediatr Gastroenterol Hepatol
Nutr. 17:80–84. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
van Dorp SM, Smajlović E, Knetsch CW,
Notermans DW, de Greeff SC and Kuijper EJ: Clinical and
microbiological characteristics of Clostridium difficile
infection among hospitalized children in the Netherlands. Clin
Infect Dis. 64:192–198. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lamont JT and Theodore E: Woodward award.
How bacterial enterotoxins work: Insights from in vivo studies.
Trans Am Clin Climatol Assoc. 113:167–180. 2002.PubMed/NCBI
|
|
9
|
Schutze GE and Willoughby RE: Committee on
infectious disease, American Academy of Pediatrics. Clostridium
difficile infection in infants and children. Pediatrics.
131:196–200. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zilberberg MD, Tillotson GS and McDonald
C: Clostridium difficile infections among hospitalized
children, United States, 1997-2006. Emerg Infect Dis. 16:604–609.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kim J, Smathers SA, Prasad P, Leckerman
KH, Coffin S and Zaoutis T: Epidemiological features of
Clostridium difficile-associated disease among inpatients at
children's hospitals in the United States, 2001-2006. Pediatrics.
122:1266–1270. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pant C, Deshpande A, Gilroy R, Olyaee M
and Donskey CJ: Rising incidence of Clostridium difficile
related discharges among hospitalized children in the United
States. Infect Control Hosp Epidemiol. 37:104–106. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sandora TJ, Fung M, Flaherty K, Helsing L,
Scanlon P, Potter-Bynoe G, Gidengil CA and Lee GM: Epidemiology and
risk factors for Clostridium difficile infection in
children. Pediatr Infect Dis J. 30:580–584. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Edwards PT, Thurm CW, Hall M, Busing JD,
Kahn SA, Kellermayer R, Kociolek LK, Oliva-Hemker MM, Sammons JS,
Weatherly M, et al: Clostridioides difficile infection in
hospitalized pediatric patients: Comparisons of epidemiology,
testing, and treatment from 2013 to 2019. J Pediatr.
252:111–116.e1. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bryant K and McDonald LC: Clostridium
difficile infections in children. Pediatr Infect Dis J.
28:145–146. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jangi S and Lamont JT: Asymptomatic
colonization by Clostridium difficile in infants:
Implications for disease in later life. J Pediatr Gastroenterol
Nutr. 51:2–7. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lees EA, Miyajima F, Pirmohamed M and
Carrol ED: The role of Clostridium difficile in the
paediatric and neonatal gut-a narrative review. Eur J Clin
Microbiol Infect Dis. 35:1047–1057. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Adams DJ, Barone JB and Nylund CM:
Community-associated Clostridioides difficile infection in
children: A review of recent literature. J Pediatric Infect Dis
Soc. 10 (Suppl_3):S22–S26. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nylund CM, Goudie A, Garza JM, Fairbrother
G and Cohen MB: Clostridium difficile infection in
hospitalized children in the United States. Arch Pediatr Adolesc
Med. 165:451–457. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Toltzis P, Kim J, Dul M, Zoltanski J,
Smathers S and Zaoutis T: Presence of the epidemic North American
Pulsed Field type 1 Clostridium difficile strain in
hospitalized children. J Pediatr. 154:607–608. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Loo VG, Poirier L, Miller MA, Oughton M,
Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M,
et al: A predominantly clonal multi-institutional outbreak of
Clostridium difficile-associated diarrhea with high
morbidity and mortality. N Engl J Med. 353:2442–2449.
2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Miranda-Katz M, Parmar D, Dang R,
Alabaster A and Greenhow TL: Epidemiology and risk factors for
community associated clostridioides difficile in children. J
Pediatr. 221:99–106. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
El Feghaly RE, Stauber JL, Tarr PI and
Haslam DB: Viralco-infections are common and are associated with
high er bacterial burden in children with Clostridium
difficile infection. J Pediatr Gastroenterol Nutr. 57:813–816.
2013.
|
|
24
|
Crews JD, Anderson LR, Waller DK, Swartz
MD, DuPont HL and Starke JR: Risk Factors for Community-associated
Clostridium difficile-associated diarrhea in children.
Pediatr Infect Dis J. 34:919–923. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Adams DJ, Eberly MD, Rajnik M and Nylund
CM: Risk factors for community-associated Clostridium
difficile infection in children. J Pediatr. 186:105–109.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Allen UD: Canadian Paediatric Society,
Infectious Diseases, Immunization Committee. Clostridium
difficile in paediatric populations. Paediatr Child Health.
19:43–48. 2014.PubMed/NCBI
|
|
27
|
Dial S, Delaney JA, Barkun AN and Suisse
S: Use of gastric acid-suppressive agents and the risk of
community-acquired Clostridium difficile-associated disease.
JAMA. 294:2989–2995. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rexach CE, Tang-Feldman Y, Cantrell MC and
Cohen SH: Epidemiologic surveillance of Clostridium
difficile diarrhea in a freestanding pediatric hospital and a
pediatric hospital at a university medical center. Diagn Microbiol
Infect Dis. 56:109–114. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sammons JS, Toltzis P and Zaoutis TE:
Clostridium difficile infection in children. JAMA Pediatr.
167:567–573. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Furuya-Kanamori L, Stone JC, Clark J,
McKenzie SJ, Yakob L, Paterson DL, Riley TV, Doi SA and Clements
AC: Comorbidities, exposure to medications, and the risk of
community-acquired Clostridium difficile Infection: A
systematic review and Meta-analysis. Infect Control Hosp Epidemiol.
36:132–141. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Oh SH and Kang HY: Identification of
target risk groups for population-based Clostridium
difficile infection prevention strategies using a population
attributable risk approach. Int J Infect Dis. 66:107–112.
2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Czepiel J, Dróżdż M, Pituch H, Kuijper EJ,
Perucki W, Mielimonka A, Goldman S, Wultańska D, Garlicki A and
Biesiada G: Clostridium difficile infection: Review. Eur J
Clin Microbiol Infect Dis. 38:1211–1221. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kelly CP and LaMont JT: Clostridium
difficile-more difficult than ever. N Engl J Med. 59:1932–1940.
2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cohen SH, Gerding DN, Johnson S, Kelly CP,
Loo VG, McDonald LC, Pepin J and Wilcox MH: Society for Healthcare
Epidemiology of America; Infectious Diseases Society of America.
Clinical practice guidelines for Clostridium difficile
infection in adults: 2010 update by the Society for Healthcare
Epidemiology of America (SHEA) and the Infectious Diseases Society
of America (IDSA). Infect Control Hosp Epidemiol. 31:431–455.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
McDonald LC, Gerding DN, Johnson S, Bakken
JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly
C, et al: Clinical practice guidelines for Clostridium
difficile infection in adults and children: 2017 update by the
Infectious Diseases Society of America (IDSA) and Society for
Healthcare Epidemiology of America (SHEA). Clin Infect Dis.
66:e1–e48. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Luna RA, Boyanton BL Jr, Mehta S, Courtney
EM, Webb CR, Revell PA and Versalovic J: Rapid stool-based
diagnosis of Clostridium difficile infection by real-time
PCR in a children's hospital. J Clin Microbiol. 49:851–857.
2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Li Z, Dong N, Hao J, Ouyang Z, Qiang C,
Yang Y, Mi C, Niu Y, Yang J, Wen B, et al: Clostridioides difficile
infection in infants: A case report and literature review. Gut
Pathog. 29(31)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gnocchi M, Gagliardi M, Gismondi P, Gaiani
F, De' Angelis GL and Esposito S: Updated Management guidelines for
clostridioides difficile in paediatrics. Pathogens.
9(291)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Stanescu GL, Nedelcuta RM, Dop D, Diaconu
R, Calin G, Niculescu EC, Gheonea C, Stanescu R, Anghelina L and
Stanescu MR: Brain abscess of unknown etiology in a 2-year-old
child: A case report. Rom J Morphol Embryol. 56:1201–1204.
2015.PubMed/NCBI
|
|
40
|
Johnson S, Lavergne V, Skinner AM,
Gonzales-Luna AJ, Garey KW, Kelly CP and Wilcox MH: Clinical
practice guideline by the Infectious Diseases Society of America
(IDSA) and Society for Healthcare Epidemiology of America (SHEA):
2021 focused update guidelines on management of Clostridioides
difficile infection in adults. Clin Infect Dis. 73:e1029–e1044.
2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Stultz JS, Hopp J, Orndahl CM, Omecene NE
and Pakyz AL: Changes in metronidazole and vancomycin utilization
for nonsevere Clostridioides difficile infection among institutions
caring for children. Pediatr Infect Dis J. 40:634–636.
2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Yin J, Kociolek LK, Same RG, Hsu AJ, Amoah
J and Tamma PD: Oral vancomycin may be associated with earlier
symptom resolution than metronidazole for hospitalized children
with nonsevere Clostridiodes difficile infections. Open Forum
Infect Dis. 6(ofz492)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cornely OA, Crook DW, Esposito R, Poirier
A, Somero MS, Weiss K, Sears P and Gorbach S: OPT-80-004 Clinical
Study Group. Fidaxomicin versus vancomycin for infection with
Clostridium difficile in Europe, Canada, and the USA: A
double-blind, non-inferiority, randomised controlled trial. Lancet
Infect Dis. 12:281–289. 2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
D'Ostroph AR and So TY: Treatment of
pediatric Clostridium difficile infection: A review on
treatment efficacy and economic value. Infect Drug Resist.
10:365–375. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wolf J, Kalocsai K, Fortuny C, Lazar S,
Bosis S, Korczowski B, Petit A, Bradford D, Croos-Dabrera R, Incera
E, et al: Safety and efficacy of fidaxomicin and vancomycin in
children and adolescents with Clostridioides (Clostridium)
difficile infection: A phase 3, multicenter, randomized,
single-blind clinical trial (SUNSHINE). Clin Infect Dis.
71:2581–2588. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Food and Drug Administration: DIFICID.
(Fidaxomicin) [package insert]. Whitehouse Station, NJ, Merck,
2020.
|
|
47
|
Shirley DA, Tornel W, Warren CA and Moonah
S: Clostridioides difficile infection in children: Recent updates
on epidemiology, diagnosis, therapy. Pediatrics.
152(e2023062307)2023.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Bao H, Lighter J, Dubrovskaya Y, Merchan
C, Siegfried J, Papadopoulos J and Jen SP: Oral vancomycin as
secondary prophylaxis for Clostridioides difficile infection.
Pediatrics. 148(e2020031807)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lamontagne F, Labbé AC, Haeck O, Lesur O,
Lalancette M, Patino C, Leblanc M, Laverdière M and Pépin J: Impact
of emergency colectomy on survival of patients with fulminant
Clostridium difficile colitis during an epidemic caused by a
hypervirulent strain. Ann Surg. 245:267–272. 2007.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Olivas AD, Umanskiy K, Zuckerbraun B and
Alverdy JC: Avoiding colectomy during surgical management of
fulminant Clostridium difficile colitis. Surg Infect
(Larchmt). 11:299–305. 2010.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Nicholson MR, Mitchell PD, Alexander E,
Ballal S, Bartlett M, Becker P, Davidovics Z, Docktor M, Dole M,
Felix G, et al: Efficacy of fecal microbiota transplantation for
Clostridium difficile infection in children. Clin
Gastroenterol Hepatol. 18:612–619.e1. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Shin JH, Chaplin AS, Hays RA, Kolling GL,
Vance S, Guerrant RL, Archbald-Pannone L and Warren CA: Outcomes of
a multidisciplinary clinic in evaluating recurrent Clostridioides
difficile infection patients for fecal microbiota transplant: A
retrospective cohort analysis. J Clin Med. 8(1036)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Davidovics ZH, Michail S, Nicholson MR,
Kociolek LK, Pai N, Hansen R, Schwerd T, Maspons A, Shamir R,
Szajewska H, et al: Fecal microbiota transplantation for recurrent
Clostridium difficile infection and other conditions in
children: A joint position paper from the North American Society
for Pediatric Gastroenterology, Hepatology, and Nutrition and the
European Society for Pediatric Gastroenterology, Hepatology, and
Nutrition. J Pediatr Gastroenterol Nutr. 68:130–143.
2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Malhotra S and Mohandas S: Updates and
opinions in diagnosis and treatment of clostridiodes difficile in
pediatrics. Curr Treat Options Peds. 7:203–216. 2021.
|
|
55
|
Gerding DN, Kelly CP, Rahav G, Lee C,
Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, et
al: Bezlotoxumab for prevention of recurrent Clostridium
difficile infection in patients at increased risk for
recurrence. Clin Infect Dis. 67:649–656. 2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Sferra TJ, Merta T, Neely M, Murta de
Oliveira C, Lassaletta A, Fortuny Guasch C, Dorr MB, Winchell G, Su
FH, Perko S, et al: Double-blind, placebo-controlled study of
bezlotoxumab in children receiving antibacterial treatment for
clostridioides difficile infection (MODIFY III). J Pediatric Infect
Dis Soc. 12:334–341. 2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Garey KW, McPherson J, Dinh AQ, Hu C, Jo
J, Wang W, Lancaster CK, Gonzales-Luna AJ, Loveall C, Begum K, et
al: Efficacy, safety, pharmacokinetics, and microbiome changes of
ibezapolstat in adults with Clostridioides difficile infection: A
phase 2a multicenter clinical trial. Clin Infect Dis. 75:1164–1170.
2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Carlson TJ, Endres BT, Bassères E,
Gonzales-Luna AJ and Garey KW: Ridinilazole for the treatment of
Clostridioides difficile infection. Expert Opin Investig Drugs.
28:303–310. 2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Hind C, Clifford M, Woolley C, Harmer J,
McGee LMC, Tyson-Hirst I, Tait HJ, Brooke DP, Dancer SJ, Hunter IS,
et al: Insights into the spectrum of activity and mechanism of
action of MGB-BP-3. ACS Infect Dis. 8:2552–2563. 2022.PubMed/NCBI View Article : Google Scholar
|
